中国抗体董事长、执行董事兼首席执行官梁瑞安称，非常高兴公司在《欧洲呼吸杂志子刊-开放研究》 上发表了关于SM17的临床前研究，突显了其治疗CRSwNP和IPF的潜力。这些结果表明SM17是一种极 具前景的潜在同类首创生物制剂，靶向关键的上游警报素(IL-25)。通过同时靶向Th2炎症、Th17分化和 纤维化，SM17可能为CRSwNP和IPF提供一种多方面的治疗策略，有潜力填补当前针对下游效应器疗法 存在局限性的未满足需求。 智通财经APP获悉，中国抗体-B(03681)再涨超5%，截至发稿，涨4.62%，报2.04港元，成交额1336.18万 港元。 消息面上，中国抗体宣布，其同类首创抗IL-17RB抗体SM17的临床前研究已在《欧洲呼吸杂志子刊-开 放研究》上发表。该研究显示，SM17通过双重抑制Th2/Th17通路及抗纤维化活性，显著改善慢性鼻窦 炎伴鼻息肉（CRSwNP）和特发性肺纤维化（IPF）的病理特征，支持其成为变革性疗法的潜力。 ...

Core Viewpoint - The release of the China-themed special issue of "Allergy" highlights significant advancements in the treatment of allergic diseases through biologics, showcasing the contributions of Chinese scholars to the global allergy science community [1][2]. Group 1: Publication and Impact - The special issue features 32 articles authored by Chinese scholars, focusing on various fields including allergy science, rhinology, respiratory medicine, and dermatology [1]. - "Allergy," established in 1948, has an impact factor of 12.6 in 2023, making it one of the most prestigious journals in the field of allergy science and clinical immunology [1]. - The editor-in-chief, Cezmi Akdis, praised the academic achievements of Chinese scholars, noting their positive influence on the global allergy science field [1]. Group 2: Advances in Treatment - Biologics are identified as a promising direction for treating allergic diseases, with increasing clinical experience expected to benefit more patients with difficult-to-treat and severe conditions [2]. - A Chinese consensus document on the use of biologics for chronic rhinosinusitis with nasal polyps was published, providing authoritative guidance on patient selection, treatment protocols, and efficacy evaluation [2]. - The special issue also includes research on the mechanisms of asthma related to environmental pollution, gut microbiome dysbiosis, and drug allergies, contributing innovative insights to the global allergy discipline [2].